Orencia is the only immunoscience product in Bristol-Myers Squibb’s (BMY) portfolio. Orencia is a fusion protein approved for the treatment of moderate to severe rheumatoid arthritis and other related issues. The drug prevents further damage to the bones and joints. The chart below compares Orencia sales since 1Q16.
As Orencia is approved for the treatment of moderate to severe rheumatoid arthritis, it may also be used in combination with other therapies except for TNF antagonists.
Orencia reported revenues of $662.0 million in 4Q17 for 6.0% growth in revenues compared to $625.0 million during 4Q16. The revenues from the US markets totaled $461.0 million during 4Q17 for 9.0% growth compared to revenues of $423.0 million during 4Q16.
For fiscal 2017, Orencia reported revenues of ~$2.5 billion for ~9.0% growth in revenues compared to ~$2.3 billion during 4Q16. The revenues from the US markets totaled ~$1.7 billion during 2017, representing 11.0% growth compared to revenues of ~$1.5 billion during 2016.
Orencia reported positive growth in revenues for its US markets and international markets due to the increase in the demand for the drug.
The established brands portfolio includes drugs from virology and other therapeutic areas. The revenues for other brands reported 2.0% growth to $595.0 million during 4Q17 compared to $581.0 million during 4Q16. For fiscal 2017, the overall revenues for other brands totaled $2.1 billion for a 7.0% decrease in revenues compared to ~$2.3 million during 2016.
The international markets reported lower sales of products in other brands, while the US markets reported growth of ~7.0% in revenues from other brands during 3Q17. The revenues from international markets decreased due to patent expiry across all major markets.